High accuracy and detection to identify tumor variants from degraded and low input samples as well as samples with limited DNA abundance

Library preparation kit adds to Twist’s portfolio of tools to enable liquid biopsy applications

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today launched the cfDNA Library Preparation Kit to enable liquid biopsy research.

Liquid biopsies have gained prominence in critical applications such as cancer screening, including multi-cancer early detection screening and monitoring for minimal residual disease (MRD). Liquid biopsy tests are designed to accurately identify tumor variants within circulating tumor DNA (ctDNA), which are often difficult to detect due to degraded or limited DNA presence. The Twist cfDNA Library Preparation Kit was purpose-built to maximize the number of unique cfDNA molecules that are captured in library preparation, for higher confidence in the accuracy and sensitivity of liquid biopsy tests.

“Liquid biopsies can be life changing for patients, enabling earlier detection of cancer and profiling each patient’s unique tumor to inform personalized treatment plans,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Even with advancements in the sensitivity of tests that have enabled the liquid biopsy field to expand, some tumor variants remain incredibly difficult for researchers to detect in the earlier stages of disease. With exceptional accuracy and sensitivity enabled by high conversion rates, the Twist cfDNA Library Preparation Kit can help push the limit of detection and detect lower frequency variants that can be missed by other on market library preparation solutions.”

The Twist cfDNA Library Preparation Kit adds to Twist’s growing portfolio of tools to support the research and development of liquid biopsy assays, which also includes the recently launched Twist cfDNA Pan-Cancer Reference Standard v2. The reference standards are a tool for researchers to use in the development and quality monitoring of clinically relevant variants for developing NGS-based assays. The updated reference standards include one of the industry-leading numbers of circulating tumor DNA (ctDNA) variants and clean background cfDNA for a significantly lower background error rate. The reference standards can be seamlessly integrated into Twist’s suite of target enrichment systems and custom capture panels.

Twist cfDNA Library Preparation Kit

The Twist cfDNA Library Preparation Kit can address challenges associated with library preparation from circulating cfDNA with reliable and robust performance from as little as 1ng sample input. It can detect even rare allele variants due to its high conversion rate. The cfDNA kit protocols minimize sample handling for a streamlined workflow and results delivered within two hours. The Twist cfDNA Library Preparation Kits are available in two configurations: the cfDNA Library Preparation Kit for whole genome sequencing (WGS) workflows and the Twist Library Preparation and Hyb Mix Kit for target enrichment.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube | Instagram

Twist Bioscience Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of the Twist cfDNA Library Preparation Kit to maximize the number of unique cfDNA molecules that are captured in library preparation, push the limit of detection and detect lower frequency variants that can be missed by other on market library preparation solutions, address challenges associated with library preparation from circulating cfDNA with reliable and robust performance from as little as 1ng sample input, and detect rare allele variants. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 2, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240206958346/en/